Sunday, July 6, 2025 7/6/2025

Targeting REV-ERB to treat Alzheimer's disease

Award Number: RF1AG060769
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2019
PERIOD OF PERFORMANCE END DATE: 06/30/2024

Group Awards By:

View Award Description

Targeting REV-ERB to treat Alzheimer's disease - Alzheimer's disease (AD) is a progressive neurodegenerative disease with clinical features that include memory loss, cognitive impairment and dementia. According to 2017 data from the Alzheimer's Association, AD is the 6th leading cause of death in the U.S. and will cost the nation $259 billion dollars this year. More than 5 million Americans currently live with the diagnosis of AD and it is expected to increase to as much as 16 million by 2050. Current treatments for AD have very limited efficacy and thus there is a significant need for improved pharmacological therapies. AD is characterized by the formation of senile plaques and neurofibrillary tangles in the grey matter of affected individuals. The senile plaques are composed of extracellular deposition of insoluble amyloid beta (Aβ) peptides that are typically associated with a wealth of microglia (brain resident macrophages) and astrocytes. It is generally recognized that the extracellular accumulation of Aβ is a key event the pathogenesis of AD. Inflammation induced by accumulation of Aβ is believed to be a crucial factor underlying the neural dysfunction and microglia and bone marrow derived phagocytes recruited to the plaques are fundamental to the pathogenesis of AD. We discovered that the REV-ERB nuclear receptors play a critical role in regulation of neuroinflammation and that pharmacological activation of REV-ERB effectively reduces neuroinflammation and improves cognitive function in a model of AD. The goal of this project is to develop optimized REV-ERB agonists that may be effective agents for reduction of neuroinflammation in treatment of Alzheimer's disease and, potentially, other neurodegenerative disorders associated with neuroinflammation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$43,003 )
2025	2019	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Aging Research	000	7	10/1/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$43,003
														Subtotal = -$43,003

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2019	UNIVERSITY OF HEALTH SCIENCES AND PHARMACY IN ST. LOUIS	1 PHARMACY PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Aging Research	001	6	3/15/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2024	2019	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Aging Research	000	7	1/12/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2019	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Aging Research	001	7	1/26/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,987,705
2023	2019	UNIVERSITY OF HEALTH SCIENCES AND PHARMACY IN ST. LOUIS	1 PHARMACY PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Aging Research	000	6	1/25/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$1,987,705
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	ST. LOUIS COLLEGE OF PHARMACY	4588 PARKVIEW PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Aging Research	000	6	10/15/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $3,683,677 )
2019	2019	ST. LOUIS COLLEGE OF PHARMACY	4588 PARKVIEW PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Aging Research	000	6	8/20/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$3,683,677
2019	2019	ST. LOUIS COLLEGE OF PHARMACY	4588 PARKVIEW PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Aging Research	001	6	8/23/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $3,683,677

Grand Total All Awards = $3,640,674

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting REV-ERB to treat Alzheimer's disease

Award Number: RF1AG060769

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2019

PERIOD OF PERFORMANCE END DATE: 06/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer